---
created: 2025-04-13
updated: 2025-04-13T10:52
id: kWwtKroek7
specialty: immuno
specialty_id: 117
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::pembrolizumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::pembrolizumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::cancer-immunotherapy
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::4-loweryield"
type: flashcard
---

# Question
Because Pembrolizumab targets a peripheral tolerance mechanism, patients taking this drug can develop autoimmune disorders of **endocrine** organs

---

# Answer
Ex thyroid, pancreas, pituitary gland, and the kidney  Inflammation of each endocrine organ can cause dysfunctions one would expect (kidney - nephritic syndrome, pancreas - T1DM ...)